Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma: Molecular Therapy
3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization | ACS Biomaterials Science & Engineering
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology
Frontiers | A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy
How is Osteosarcoma treatment different from Ewing sarcoma treatment?
Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer
Trial Results May Help Inform Treatments for Ewing Sarcoma - NCI
Ewing Sarcoma Treatment (PDQ®)–Patient Version - NCI
Frontiers | Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment
Targeted Therapy of Ewing's Sarcoma
Understanding sarcoma, one of the rarest cancers - Baylor College of Medicine Blog Network
Ewing Sarcoma Treatment (PDQ®)–Patient Version - NCI
Cellular immunotherapy strategies for Ewing sarcoma | Immunotherapy
Frontiers | The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A review
Emerging trends in immunotherapy for pediatric sarcomas | Journal of Hematology & Oncology | Full Text
Immunosuppression in the Ewing sarcoma tumor microenvironment. Low... | Download Scientific Diagram